REPLY
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2023, which will be submitted for approval to the Shareholders’ Meeting to be held on first call in Turin on 23 April 2024.
The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.
All indicators are positive for the period. Consolidated EBITDA was €352.1 million, an increase of 3.5% compared to €340.3 million at December 2022 (growth is 20% net of the COVID funds released in 2022).
EBIT, from January to December, was at €292.7 million, which is an increase of 2.5% compared to €285.5 million at December 2022 (growth is 22.7% net of the COVID funds released in 2022).
The Group net profit was at €186.7 million. In 2022, the corresponding value was €191.0 million.
Following the results achieved in 2023, the Reply Board of Directors decided to propose a dividend distribution of €1 per share to the next Shareholders’ Meeting, which will be payable on 22 May 2024, with the dividend date set on 20 May 2024 (record date 21 May 2024).
As at 31 December 2023, the Group’s net financial position has been positive at €204.9 million (€70.6 million at 31 December 2022). As at 30 September 2023, the net financial position was positive at €189.7 million.
"2023," stated Mario Rizzante, Reply's Chairman, "was the year in which the world became definitively aware that a great new revolution was just around the corner: the advent of artificial intelligence. Reply was able to ride this moment of great discontinuity by closing a growing financial year, but above all by establishing itself among the new leaders in the sector."
"This positioning - continues Mario Rizzante - was possible because Reply, in 2023, was able to capitalise on years of investment made in artificial intelligence, an area where we began operating with our first competence centres as early as 2017. This know-how within the group has allowed us, in a few months, not only to set up dedicated AI units within all the group companies, but above all to specialise more than 20 companies on the introduction of artificial intelligence into the main industrial sectors."
"The future that lies ahead" Mario Rizzante concludes "is still to be written. In a short time, we will be living in a union of automation, artificial intelligence, digital interfaces and connected objects. In front of us there is a great opportunity and at the same time a challenge that, as Reply, we intend to seize and transform into new spaces of growth for our Group."
The manager responsible for preparing the company's financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries.
REPLY
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313708049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth8.7.2025 14:00:00 CEST | Press release
ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to the role of President and Chief Technology Officer, where he will continue to guide the company’s technological innovation roadmap. Shawn O’Neil, most recently Chief Commercial Officer, has been appointed Chief Executive Officer. In turn, Pete England has been promoted to Chief Commercial Officer. “These leadership changes mark an important milestone in ViaLase’s evolution,” said Tom Frinzi, Executive Chairman of the Board. “Tibor has done an extraordinary job building a world-class R&D and clinical organization, laying the foundation for what promises to be a major advancement in glaucoma care. His track record as an entrepreneu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom